Class action lawsuit filed on behalf of investors in Teva
Complaint alleges Teva failed to disclose the poor performance of its US generics business and the subsequent goodwill impairment charge stemming from the company’s purchase of Actavis Generics.
Holzer & Holzer, LLC has announced that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Teva Pharmaceutical Industries Ltd (“Teva” or the “Company”) American Depositary Shares (“ADSs”) on the New York Stock Exchange and/or common stock on the Tel Aviv Stock Exchange (“TASE”) between 15 November 2016 and 2 August 2017. The complaint alleges Teva issued false and misleading statements during that time.
Specifically, the Complaint alleges Teva failed to disclose the poor performance of its U.S. generics business and the subsequent goodwill impairment charge stemming from the Company’s purchase of Actavis Generics. On 3 August 2017, Teva announced a $6.1 million goodwill impairment charge in the second quarter of 2016. The price of Teva common stock has declined following the report.
The case is pending in the United States District Court for the Eastern District of Pennsylvania and the deadline to move for appointment as lead plaintiff is 23 October 2017.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.